Having a leading position in the Greek market, Lavipharm has set the foundations for capturing a major market share internationally.

Its strongest elements are its strategic focus on the pharmacy market, its research and development and its international co-operations.

In Greece, Lavipharm develops, manufactures, represents, markets and distributes its own R&D products, as well as products for third parties, while it sustain its leading position as a collaborator in the services sector.

Lavipharm's market shares in the most important therapeutic categories that distributes are:
-1st position in antiseptics with 52.8% market share.
-1st position in Transdermal NTG (drug category concerning cardiovascular diseases) with 46.5% market share.
-2nd position in nootropics (drug category concerning Central Nervous System) with 36% market share.
-4th place in anti-lice products with 9.7% market share.

In the dermocosmetic sector, Lavipharm holds a 4.6% market share in the pharmacy market, through the own R&D products of its subsidiary Castalia Laboratoires Dermatologiques (PUIRCP 2003).

In the Services Sector, Lavipharm's sales network is based on the largest private pharmaceutical wholesaler in Greece, LAS, as well as on the largest 3rd party logistics distribution center in the health care sector, Pharma Logistics, with a market share of 21% (first position).

On an international level, Lavipharm is active in Research and Development a pioneer in drug delivery systems, cosmetic delivery systems.

In a competitive environment that is constantly evolving, Lavipharm collaborates with well-known companies in the pharmaceutical industry in order to be innovative and open new horizons in its business activities.